Filippi Luca, de Libero Cinzia, Zamma Gallarati Barbara, Fortunato Pina, Piozzi Elena
Neonatal Intensive Care Unit, Medical Surgical Fetal-Neonatal Department.
Pediatric Ophthalmology Unit, "A. Meyer" University Children's Hospital, Florence.
Medicine (Baltimore). 2018 Nov;97(45):e13002. doi: 10.1097/MD.0000000000013002.
Studies performed in animal models of corneal neovascularization suggested the possible efficacy of a treatment with propranolol. Corneal neovascularization is one of the most feared complications of Stevens-Johnson syndrome that frequently involves ocular surface. We report the first 2 patients with severe ocular neo-vascularization treated with different degrees of success, with propranolol eye drops.
Two patients with corneal neovascularization complicating the Stevens-Johnson syndrome, not responsive to steroids and cyclosporine, were treated with propranolol eye drops.
Corneal neovascularization was detected by ophthalmoscopic evaluation.
Topical treatment with propranolol eye drops at different concentrations.
Both patients reported dramatic subjective benefits (reduction of photophobia and discomfort) without adverse effects, and in the patient with a less advanced disease, an objective reduction of neovascularization and an improved visual acuity was observed.
This experience suggests that propranolol might be an inexpensive, safe and effective treatment in counteracting the progression of corneal neovascularization.
在角膜新生血管化动物模型中进行的研究表明,普萘洛尔治疗可能有效。角膜新生血管化是史蒂文斯-约翰逊综合征最可怕的并发症之一,常累及眼表。我们报告了首例使用普萘洛尔滴眼液治疗严重眼部新生血管化取得不同程度成功的2例患者。
2例角膜新生血管化并发史蒂文斯-约翰逊综合征且对类固醇和环孢素无反应的患者接受了普萘洛尔滴眼液治疗。
通过检眼镜评估检测到角膜新生血管化。
使用不同浓度的普萘洛尔滴眼液进行局部治疗。
2例患者均称主观上有显著改善(畏光和不适感减轻)且无不良反应,病情较轻的患者角膜新生血管化客观上有所减轻,视力有所提高。
该经验表明,普萘洛尔在对抗角膜新生血管化进展方面可能是一种廉价、安全且有效的治疗方法。